BRPI0909267A2 - composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, métodos para tratar um animal de sangue quente que sofre de um a condição e para tratar o câncer em um animal de sangue quente - Google Patents

composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, métodos para tratar um animal de sangue quente que sofre de um a condição e para tratar o câncer em um animal de sangue quente

Info

Publication number: BRPI0909267A2
Authority: BR; Brazil
Prior art keywords: warm; pharmaceutical composition; blooded animal; treating; preparation
Prior art date: 2008-03-28

Application number

BRPI0909267A

Other languages

English (en)

Inventor

Jane Hill Kathryn

Frances Bateman Nicolas

Richard Gellert Paul

Original Assignee

Array Biopharma Inc

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-28

Filing date

2009-03-26

Publication date

2017-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909267(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-26 Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc

2017-05-30 Publication of BRPI0909267A2 publication Critical patent/BRPI0909267A2/pt

2020-07-07 Publication of BRPI0909267B1 publication Critical patent/BRPI0909267B1/pt

2021-05-25 Publication of BRPI0909267B8 publication Critical patent/BRPI0909267B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BRPI0909267A 2008-03-28 2009-03-26 composição farmacêutica e processo para a preparação de uma composição farmacêutica BRPI0909267B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4037208P	2008-03-28	2008-03-28
US61/040372		2008-03-28
PCT/GB2009/050293 WO2009118562A1 (en)	2008-03-28	2009-03-26	Pharmaceutical composition 271

Publications (3)

Publication Number	Publication Date
BRPI0909267A2 true BRPI0909267A2 (pt)	2017-05-30
BRPI0909267B1 BRPI0909267B1 (pt)	2020-07-07
BRPI0909267B8 BRPI0909267B8 (pt)	2021-05-25

Family

ID=40792932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909267A BRPI0909267B8 (pt)	2008-03-28	2009-03-26	composição farmacêutica e processo para a preparação de uma composição farmacêutica

Country Status (30)

Country	Link
US (12)	US20090246274A1 (pt)
EP (1)	EP2271321B1 (pt)
JP (2)	JP5547710B2 (pt)
KR (1)	KR101650958B1 (pt)
CN (1)	CN102046156B (pt)
AR (2)	AR071100A1 (pt)
AU (1)	AU2009229204B2 (pt)
BR (1)	BRPI0909267B8 (pt)
CA (1)	CA2718653C (pt)
CL (1)	CL2009000765A1 (pt)
CO (1)	CO6311068A2 (pt)
CY (1)	CY1113279T1 (pt)
DK (1)	DK2271321T3 (pt)
EC (1)	ECSP10010578A (pt)
ES (1)	ES2387942T3 (pt)
HR (1)	HRP20120657T1 (pt)
IL (1)	IL208206A0 (pt)
MX (1)	MX2010010671A (pt)
MY (1)	MY157492A (pt)
NZ (1)	NZ588849A (pt)
PE (1)	PE20091755A1 (pt)
PL (1)	PL2271321T3 (pt)
PT (1)	PT2271321E (pt)
RS (1)	RS52409B (pt)
SA (1)	SA109300195B1 (pt)
TW (1)	TWI433840B (pt)
UA (1)	UA101654C2 (pt)
UY (1)	UY31737A (pt)
WO (1)	WO2009118562A1 (pt)
ZA (1)	ZA201006766B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
PT2903968T (pt)	2012-10-02	2017-03-13	Gilead Sciences Inc	Inibidores de desmetilases de histonas
EP2961736B1 (en)	2013-02-27	2018-04-11	Gilead Sciences, Inc.	Inhibitors of histone demethylases
EP3126345A1 (en)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibitors of histone demethylases
EA201790154A1 (ru)	2014-08-27	2017-08-31	Джилид Сайэнс, Инк.	Соединения и способы для ингибирования гистоновых деметилаз
CN121443286A (zh) *	2023-05-25	2026-01-30	地图之光治疗股份有限公司	用于治疗神经障碍的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022852A (en)	1993-10-22	2000-02-08	Hexal Ag	Pharmaceutical composition containing cyclosporin A
DE69525740T2 (de)	1994-04-07	2002-10-24	Smithkline Beecham P.L.C., Brentford	Spezielle halofantrinhaltige Zusammensetzungen
CA2221145A1 (en)	1995-05-19	1996-11-21	Abbott Laboratories	Self-emulsifying formulations of lipophilic drugs
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
MY126358A (en) *	1996-03-22	2006-09-29	Glaxo Group Ltd	Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en)	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
KR20000069900A (ko)	1997-01-30	2000-11-25	한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
US20030104048A1 (en)	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6372251B2 (en)	1999-06-11	2002-04-16	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20030236236A1 (en)	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ITMI20011337A1 (it)	2001-06-26	2002-12-26	Farmatron Ltd	Composizioni farmaceutiche orali a rilascio modificato del principio attivo
SI2275102T1 (sl)	2002-03-13	2015-12-31	Array Biopharma, Inc.	N3 alkilirani benzimidazol derivati kot MEK inhibitorji
MXPA05000232A (es) *	2002-06-21	2005-06-17	Transform Pharmaceuticals Inc	Composiciones farmaceuticas con disolucion mejorada.
AU2003267231A1 (en)	2002-09-20	2004-04-08	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US20040127551A1 (en)	2002-12-27	2004-07-01	Kai Zhang	Taxane-based compositions and methods of use
AR046811A1 (es) *	2003-09-02	2005-12-28	Imran Ahmed	Formas de dosificacion oral de ziprasidona de liberacion sostenida
US20050096365A1 (en)	2003-11-03	2005-05-05	David Fikstad	Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en)	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es)	2003-12-23	2005-12-21	Novartis Ag	Formulaciones farmaceuticas de bisfosfonatos
BRPI0418427A (pt)	2004-01-30	2007-06-12	Pfizer Italia Srl	formulações farmacêuticas de matriz semi-sólida
KR20050104152A (ko) *	2004-04-28	2005-11-02	최승호	경구용 약물의 흡수를 증진하는 약제학적 조성물
US20070060610A1 (en)	2005-06-16	2007-03-15	Wempe Michael F	Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US9561178B2 (en)	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
BRPI0909185A2 (pt)	2008-03-20	2015-08-25	Virun Inc	Derivado de vitamina e e seus usos
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان

2009
- 2009-03-25 SA SA109300195A patent/SA109300195B1/ar unknown
- 2009-03-26 JP JP2011501300A patent/JP5547710B2/ja active Active
- 2009-03-26 MY MYPI2010004504A patent/MY157492A/en unknown
- 2009-03-26 DK DK09726304.0T patent/DK2271321T3/da active
- 2009-03-26 CA CA2718653A patent/CA2718653C/en active Active
- 2009-03-26 WO PCT/GB2009/050293 patent/WO2009118562A1/en not_active Ceased
- 2009-03-26 NZ NZ588849A patent/NZ588849A/en unknown
- 2009-03-26 CN CN200980120227.7A patent/CN102046156B/zh active Active
- 2009-03-26 EP EP09726304A patent/EP2271321B1/en active Active
- 2009-03-26 ES ES09726304T patent/ES2387942T3/es active Active
- 2009-03-26 PL PL09726304T patent/PL2271321T3/pl unknown
- 2009-03-26 AU AU2009229204A patent/AU2009229204B2/en active Active
- 2009-03-26 US US12/411,865 patent/US20090246274A1/en not_active Abandoned
- 2009-03-26 UA UAA201012519A patent/UA101654C2/uk unknown
- 2009-03-26 KR KR1020107023140A patent/KR101650958B1/ko active Active
- 2009-03-26 PT PT09726304T patent/PT2271321E/pt unknown
- 2009-03-26 TW TW098109981A patent/TWI433840B/zh active
- 2009-03-26 MX MX2010010671A patent/MX2010010671A/es active IP Right Grant
- 2009-03-26 HR HRP20120657AT patent/HRP20120657T1/hr unknown
- 2009-03-26 BR BRPI0909267A patent/BRPI0909267B8/pt active IP Right Grant
- 2009-03-26 UY UY0001031737A patent/UY31737A/es not_active Application Discontinuation
- 2009-03-26 RS RS20120357A patent/RS52409B/sr unknown
- 2009-03-27 AR ARP090101107A patent/AR071100A1/es not_active Application Discontinuation
- 2009-03-27 CL CL2009000765A patent/CL2009000765A1/es unknown
- 2009-03-27 PE PE2009000461A patent/PE20091755A1/es not_active Application Discontinuation
2010
- 2010-09-16 IL IL208206A patent/IL208206A0/en active IP Right Grant
- 2010-09-21 ZA ZA2010/06766A patent/ZA201006766B/en unknown
- 2010-10-28 CO CO10134209A patent/CO6311068A2/es active IP Right Grant
- 2010-10-28 EC EC2010010578A patent/ECSP10010578A/es unknown
2011
- 2011-11-10 US US13/293,368 patent/US20120114750A1/en not_active Abandoned
2012
- 2012-08-13 CY CY20121100732T patent/CY1113279T1/el unknown
2013
- 2013-01-23 US US13/747,853 patent/US20130195971A1/en not_active Abandoned
2014
- 2014-02-17 JP JP2014027398A patent/JP2014114320A/ja active Pending
2015
- 2015-10-15 US US14/884,343 patent/US20160030574A1/en not_active Abandoned
2016
- 2016-11-10 US US15/348,053 patent/US20170056375A1/en not_active Abandoned
2018
- 2018-06-29 US US16/023,102 patent/US20190030004A1/en not_active Abandoned
2019
- 2019-08-23 AR ARP190102398A patent/AR116001A2/es not_active Application Discontinuation
- 2019-10-09 US US16/597,237 patent/US20200179344A1/en not_active Abandoned
2021
- 2021-05-06 US US17/313,312 patent/US11813246B2/en active Active
2023
- 2023-10-10 US US18/484,334 patent/US12220403B2/en active Active
- 2023-10-10 US US18/484,337 patent/US12465593B2/en active Active
2024
- 2024-09-03 US US18/823,274 patent/US12364684B2/en active Active
- 2024-09-03 US US18/823,257 patent/US12318367B2/en active Active

Also Published As

Publication number	Publication date
AU2009229204A1 (en)	2009-10-01
US20220087982A1 (en)	2022-03-24
US20190030004A1 (en)	2019-01-31
US11813246B2 (en)	2023-11-14
RU2491920C2 (ru)	2013-09-10
ZA201006766B (en)	2011-05-25
ES2387942T3 (es)	2012-10-04
US20130195971A1 (en)	2013-08-01
ECSP10010578A (es)	2010-11-30
PE20091755A1 (es)	2009-12-13
EP2271321A1 (en)	2011-01-12
CY1113279T1 (el)	2016-04-13
JP2011515455A (ja)	2011-05-19
RU2010143906A (ru)	2012-05-10
DK2271321T3 (da)	2012-08-27
UY31737A (es)	2009-11-10
KR101650958B1 (ko)	2016-08-24
HK1156844A1 (zh)	2012-06-22
NZ588849A (en)	2012-06-29
CO6311068A2 (es)	2011-08-22
US20090246274A1 (en)	2009-10-01
EP2271321B1 (en)	2012-06-13
CN102046156B (zh)	2014-12-17
TW200946511A (en)	2009-11-16
RS52409B (sr)	2013-02-28
JP5547710B2 (ja)	2014-07-16
US12318367B2 (en)	2025-06-03
TWI433840B (zh)	2014-04-11
AU2009229204B2 (en)	2012-05-24
US20160030574A1 (en)	2016-02-04
US20240423960A1 (en)	2024-12-26
JP2014114320A (ja)	2014-06-26
US20250000848A1 (en)	2025-01-02
US12364684B2 (en)	2025-07-22
SA109300195B1 (ar)	2013-04-20
HRP20120657T1 (hr)	2012-09-30
MY157492A (en)	2016-06-15
CL2009000765A1 (es)	2011-02-11
CN102046156A (zh)	2011-05-04
CA2718653A1 (en)	2009-10-01
IL208206A0 (en)	2010-12-30
WO2009118562A1 (en)	2009-10-01
MX2010010671A (es)	2011-06-20
AR116001A2 (es)	2021-03-25
BRPI0909267B1 (pt)	2020-07-07
AR071100A1 (es)	2010-05-26
US20200179344A1 (en)	2020-06-11
PL2271321T3 (pl)	2013-03-29
US12220403B2 (en)	2025-02-11
US20240041835A1 (en)	2024-02-08
US20170056375A1 (en)	2017-03-02
UA101654C2 (uk)	2013-04-25
BRPI0909267B8 (pt)	2021-05-25
CA2718653C (en)	2016-02-09
US12465593B2 (en)	2025-11-11
US20120114750A1 (en)	2012-05-10
US20240041834A1 (en)	2024-02-08
KR20110005246A (ko)	2011-01-17
HK1149476A1 (en)	2011-10-07
PT2271321E (pt)	2012-08-16

Publication	Publication Date	Title
BRPI0921687A2 (pt)	2015-08-18	Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BR112014003296A2 (pt)	2017-03-14	composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
BRPI0919488A2 (pt)	2015-12-01	composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BRPI1009022A2 (pt)	2016-03-08	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0914233A2 (pt)	2015-11-03	composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
BRPI0812521A2 (pt)	2015-06-23	Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0822398A2 (pt)	2014-11-18	Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0809655A2 (pt)	2014-10-07	Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0921317A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BR112012028530A2 (pt)	2017-12-19	composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BRPI0922122A2 (pt)	2017-08-01	composições e métodos para tratamento de doença celíaca.
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0906805A2 (pt)	2015-07-14	Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
BRPI0818426A2 (pt)	2017-06-13	produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI1005153A2 (pt)	2019-09-24	composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-24	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-07-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/07/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF